A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

BACKGROUND: Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and glycopyrronium. Previous studies have compared glycopyrronium with open-label tiotropium. In the GLOW5 study, we compare gl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chapman, Kenneth R, Beeh, Kai-Michael, Beier, Jutta, Bateman, Eric D, D’Urzo, Anthony, Nutbrown, Robert, Henley, Michelle, Chen, Hungta, Overend, Tim, D’Andrea, Peter
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907130/
https://ncbi.nlm.nih.gov/pubmed/24438744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2466-14-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars